Study aim: The effect of Edaravone on the course of clinical signs in patients with COVID-19 will be evaluated. Design: A clinical trial with a control group, with parallel groups, simple-randomly assigned to intervention and control groups, Phase 3, 38 patients Settings and conduct: This study will be performed in Imam Reza Hospital, Tabriz, Iran. 38 patients will be divided into two groups (15 in each group) by simple randomization. Patients in the control group will be prescribed a standard regimen. Patients in the intervention group, in addition to the treatment approved by the Ministry of Health, will receive 30 mg Edaravone by intravenous infusion for 3 day. Lungs' CT scan, hospitalization period, need to intubation, and mortality rate will be assessed. Participants/Inclusion and exclusion criteria: Patients with COVID-19 with mild to moderate pneumonia; 18 years to 80 Years; both genders. Exclusion criteria: Pregnant or lactating women; patients with an active thrombotic event; severe respiratory failure. Intervention groups: will receive a standard regimen for COVID-19 plus Edaravone. Control group: will receive a standard regimen for COVID-19. Main outcome variables: Symptoms of the disease; mortality rate; hospitalization period